Document is current
Any future updates will be listed below
-
Authors
Uchida, Daigaku https://orcid.org/0000-0001-9115-8089
Sato, Yasunori
Kanatsuka, Azuma
Kuribayashi, Nobuichi
Nakamura, Susumu
Ko, Shigetake
Maegawa, Hiroshi
,
Hasegawa, Atsushi
Yamada, Daishiro
Yoshimura, Haruhiko
Yokoyama, Hiroki
Sakai, Kentaro
Kimura, Kenichi
Kudo, Mikihiko
Ishigaki, Yasushi
Yamaguchi, Hiroshi
Okuguchi, Fuminobu
Yano, Nobuki
Seino, Hiroaki
Ajihara, Takashi
Yamazaki, Katsuya
Chiba, Yasuko
Takamura, Hiroshi
Kato, Mitsutoshi
Yamamoto, Naoyuki
Maeda, Hajime
Takeda, Hiroshi
Arai, Keiko
Iemitsu, Kotaro
Takai, Masahiko
Takaki, Masato
Kono, Yuki
Kato, Sumio
Sekine, Osamu
Oishi, Mariko
Hosokawa, Akiko
Iwasaki, Koichi
Okada, Akira
Sugimoto, Hidekatsu
Tanaka, Kokichi
Minami, Masae
Abe, Katsushige
Yagi, Noriharu
-
Funding
Funding for this research was provided by:
Japan Diabetes Clinical Data Manegiment Study Group
- License Information
-
More Information
Article History
Received: 28 August 2024
Accepted: 19 November 2024
First Online: 10 December 2024
Declarations
:
: Author DU has received lecture fees from Novo Nordisk Pharma Ltd., Novartis Pharma KK, Eli Lilly Japan KK., Daiichi Sankyo Co., Ltd., Tanabe Mitsubishi Pharma Co., Ltd., Otsuka Pharma Co., Ltd., Kowa Co., Ltd., Sanofi KK., Sumitomo Pharma Co., Ltd., Kissei Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd. Author YS has received lecture fees from Mochida Pharma Co., Ltd. and clinical research expenses from Eli Lilly Japan KK. Author NK has received lecture fees from Novo Nordisk Pharma Ltd. Author HM has received lecture fees from Sanofi, Nippon Boehringer Ingelheim Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma LTD., Sumitomo Dainippon Pharma Co., Ltd., Astellas Pharma Inc, Eli Lilly Japan K.K. MSD, and total amount of scholarships (incentives) from Takeda Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Kowa Company, Ltd., Nipro Corporation, and Teijin Pharma Co., Ltd. Author AK, Author SN, and Author SK declare that they have no conflicts of interest.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Written informed consent was not required from patients because of the retrospective nature of this study. The option to ‘opt out’ and the procedures for doing so were made clear through a poster describing the study in each clinic. The protocol for this research project was approved by a suitably constituted Ethics Committee of the institution, the JDDM Ethics Committee (approval No. JDDM2023-2, 4 June 2023).
